Follow the latest news on emerging brain tumour treatments with commentary from a 10+ year survivor of a high grade glioma. News features on metabolic treatments and novel therapies will be prioritised.
| Platform |  | Pricing | Freemium | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 130 | Founded | 4 years ago | Last Issue | 10 days ago |
| Active | |||||
Read this Newsletter
andrewscarborough.substack.comLatest Issues
Seizure glasses vs blue light blockers
When I was diagnosed with a malignant brain tumour in 2013 I instantly found I became not just photosensitive, but also photophobic. How that manifested itself changed with time, but a degree of sensitivity persisted. Through my reading, I...
Time for change
It’s my birthday today. I’m feeling reflective and thinking about what I really want from life, but also about how I can provide real value through what I have to offer others.
In the days leading up to this moment, I noticed that I’d los...
A step forward for intranasal brain cancer drugs?
Results not to be sniffed at reveal something interesting
Intranasal delivery of drugs to treat brain tumours makes a lot of sense. You effectively bypass the blood–brain barrier by providing a more direct route from the nasal cavity to th...
The value of water testing
I just received my ‘Water Test Premium’ kit from IVARIO, an accredited water testing laboratory (ISO 17025) and a leading provider of comprehensive water tests in the UK.
This was inspired by my last post on the gadolinium water contamina...
"Green radiology" goes well beyond sustainability.
Are non-contrast MRI scans finally becoming a practical reality?
You may be surprised to learn that the impacts of contrast-enhanced MRI go well beyond the patient lying inside the scanner. While the potential risks to patients (with healt...
Key Facts
Audience Metrics
Subscribers, engagement, traffic and sponsorship for Andrew’s Substack.
| Subscribers | Engagement | 69 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
Long term brain cancer survivor, writer, researcher. Interest in metabolic therapies. Follow @cancermetstudy for more info.
Social
Frequently Asked Questions
How can I access the email archive for Andrew’s Substack?
You can find recent issues that have been published by Andrew’s Substack on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Andrew’s Substack have?
To see how many people subscribe to Andrew’s Substack, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Andrew’s Substack?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Andrew’s Substack as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Andrew’s Substack?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Andrew’s Substack using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to Andrew’s Substack?
Scroll up to where it says Related Newsletters to see other publications like Andrew’s Substack. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Andrew’s Substack?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.